Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis

Jie Deng 1,†, Yirui Ma 1,†, Qiao Liu 1, Min Du 1, Min Liu 1,* and Jue Liu 1,2,*

1 Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China
2 Institute for Global Health and Development, Peking University, Beijing 100191, China
* Correspondence: liumin@bjmu.edu.cn (M.L.); jueliu@bjmu.edu.cn (J.L.)
† These authors contributed equally to this work.

Abstract: As vaccine resources were distributed unevenly worldwide, sometimes there might have been shortages or delays in vaccine supply; therefore, considering the use of heterogeneous booster doses for Coronavirus disease 2019 (COVID-19) might be an alternative strategy. Therefore, we aimed to review the data available to evaluate and compare the effectiveness and safety of heterologous booster doses with homologous booster doses for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. We searched relevant studies up to 27 April 2022. Random-effects inverse variance models were used to evaluate the vaccine effectiveness (VE) and its 95% confidence interval (CI) of COVID-19 outcomes and odds ratio (OR) and its CI of safety events. The Newcastle–Ottawa quality assessment scale and Cochrane Collaboration’s tool were used to assess the quality of the included cohort studies. A total of 23 studies involving 1,726,506 inoculation cases of homologous booster dose and 5,343,580 inoculation cases of heterologous booster dose was included. The VE of heterologous booster for the prevention of SARS-CoV-2 infection (VEheterologous = 96.10%, VEthomologous = 84.00%), symptomatic COVID-19 (VEheterologous = 56.80%, VEthomologous = 17.30%), and COVID-19-related hospital admissions (VEheterologous = 97.40%, VEthomologous = 93.20%) was higher than homologous booster. Compared with homologous booster group, there was a higher risk of fever (OR = 1.930, 95% CI, 1.199–3.107), myalgia (OR = 1.825, 95% CI, 1.079–3.089), and malaise or fatigue (OR = 1.745, 95% CI, 1.047–2.906) within 7 days after boosting, and a higher risk of malaise or fatigue (OR = 4.140, 95% CI, 1.729–9.916) within 28 days after boosting in heterologous booster group. Compared with homologous booster group, geometric mean neutralizing titers (GMTs) of neutralizing antibody for different SARS-CoV-2 variants and response rate of antibody and gamma interferon were higher in heterologous booster group. Our findings suggested that both homologous and heterologous COVID-19 booster doses had great effectiveness, immunogenicity, and acceptable safety, and a heterologous booster dose was more effective, which would help make appropriate public health decisions and reduce public hesitancy in vaccination.

Keywords: SARS-CoV-2; COVID-19 vaccine; heterologous booster dose; homologous booster dose; effectiveness; safety; immunogenicity

1. Introduction

Caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pandemic of coronavirus disease 2019 (COVID-19) has posed an extraordinary threat and burden of disease to global public health [1]. According to the World Health Organization (WHO) COVID-19 dashboard, as of 8 July 2022, there have been more than 551.2 million confirmed cases of COVID-19, including more than 6.34 million deaths, globally [2]. Vaccination against SARS-CoV-2 is still considered a key measure to prevent infection, serious illness, hospitalization, and death, as well as control the COVID-19 pandemic [3]. As of
10 July 2022, a total of more than 12.14 billion doses of COVID-19 vaccine have been administered globally, and 5.54 million are now administered each day [2,4]. A total of 66.7% of the world population has received at least one dose of COVID-19 vaccine; however, only 20.2% of people in low-income countries have received at least one dose [4]. In 2021, WHO set the target for 70% global vaccination coverage by mid-2022 [5,6]. As of June 2022, only 58 of WHO’s 194 member states had reached the 70% target, and in low-income countries, just 37% of healthcare workers had received a complete course of primary vaccination [2,5]. Equity and availability of vaccine resources, therefore, still remain a key issue in achieving the global vaccine coverage rate target.

Emerging studies consistently showed that the initial vaccine effectiveness (VE) for the prevention of SARS-CoV-2 infection and COVID-19 disease decreased over time since vaccination [7]. Therefore, WHO proposed to give booster doses to vaccinated people who have completed the primary vaccine series to restore and prolong the VE when immunity and clinical protection rates fell below levels considered adequate in that population [8,9]. According to the latest WHO Strategic Advisory Group of Experts on Immunization (SAGE) roadmap for prioritizing use of COVID-19 vaccine, WHO recommended that countries with moderate-to-high rates of primary series coverage in higher priority-use groups should usually prioritize available resources to first achieve high booster dose coverage rates in higher priority-use groups before offering vaccine doses to lower priority-use groups [10]. However, vaccine resources were unevenly distributed worldwide, with extremely low vaccination rates in some low-income countries [5]. Additionally, sometimes there might be shortages or delays in vaccine supply [11]. Therefore, considering the use of heterogeneous booster doses for SARS-CoV-2 might be an alternative strategy to the homologous to alleviate these problems to some extent and promote the equity and rationalization of vaccine allocation. It was important to evaluate different COVID-19 booster vaccination strategies, which would help public policy decisions and reduce vaccination hesitancy.

WHO issued interim guidance summarizing existing evidence of heterologous primary and boosting SARS-CoV-2 vaccine and setting vaccination schedules on 16 December 2021 [12] and also stated that it was safe and effective to receive a different third dose of COVID-19 vaccine [3]. Au, WY. et al.’s systematic review has showed that heterologous and homologous three dose regimens work comparably well in preventing COVID-19 infections, even against different variants but remained uncertain in COVID-19-related death. The VE of two dose adenovirus vector vaccines with one mRNA vaccine in the prevention of COVID-19 infection was 88%, while the most effective regimen with three dose mRNA vaccine was 96% [13]. Li JX et al. found that a heterologous booster vaccine with an orally administered aerosolized Ad5-nCoV was safe and highly immunogenic in Chinese adults who have previously received two doses of CoronaVac as the primary series vaccination [14]; furthermore, heterologous boosting with Convidecia following initial vaccination with CoronaVac was safe and more immunogenic than homologous boosting [15], which was similar to previous studies that suggested the safety and highly immunogenicity of heterologous booster strategy [16–18]. Atmar, R. L. et al.’s study showed that more than half the recipients reported having injection-site pain, malaise, headache, or myalgia but were acceptable [19].

Since the advent of COVID-19 vaccine, as of 19 May 2022, WHO has validated 11 vaccines for COVID-19 emergency use listing (EUL) [20–22]. Inconsistent procurement of COVID-19 vaccines and limited vaccine supplies prevented some types of vaccines from being used clinically. Even though there were more and more clinical trial studies of COVID-19 boosting vaccination strategy, evidence for the effectiveness, immunogenicity, and safety of heterologous booster doses of COVID-19 vaccine remained partial and incomplete [12]. Timely evaluation of different booster vaccination strategies would help in making appropriate public health decisions, reducing public hesitancy in vaccination, and promoting rational allocation of COVID-19 vaccine resources. We aimed to compare the effectiveness, immunogenicity, and safety of heterologous booster doses with homologous booster doses for COVID-19 vaccines based on the real world and conducted a systematic
review and meta-analysis to provide an evidence-based basis for the COVID-19 boosting vaccination strategy.

2. Methods

2.1. Search Strategy and Selection Criteria

We searched studies published up to 27 April 2022 without language restrictions in PubMed, EMBASE, Web of Science, Science Direct, and Cochrane Library databases using the following search terms: (SARS-CoV-2 vaccine) OR (COVID-19 vaccine)) AND (booster dose)) AND (heterologous OR homologous).

We used EndNoteX8.2 (Thomson Research Soft, Stanford, CA, USA) to manage records. This study was strictly performed according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA in the Supplementary Materials) [23]. This study was registered on PROSPERO (CRD42022328792).

We included studies that examined the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines. The following studies will be excluded: (1) irrelevant to the subject of the meta-analysis, such as studies that did not use SARS-CoV-2 vaccination as the exposure; (2) insufficient data to calculate the rate for the effectiveness and safety of SARS-CoV-2 vaccines; (3) duplicate studies or overlapping participants; (4) qualitative researches, reviews, editorials, conference papers, case reports, or animal experiments; and (5) studies that did not clarify the identification of COVID-19. For example, the confirmed diagnosis of COVID-19 via reverse-transcription polymerase chain reaction (rt-PCR) test, serologic test, or other means was not mentioned in the text.

Studies were identified by two investigators (DJ and MYR) independently following the criteria above, while discrepancies were solved by consensus or with a third investigator (LQ).

2.2. Data Extraction

The following data will be extracted: (1) basic information of the studies, including first author, published time, and article type (preprint article or published article), study design (e.g., cohort study, case-control study, or randomized controlled trial (RCTs)), and location where the study was conducted; (2) characteristics of the study population, including population sizes, age, sex ratio (female/male), vaccination status and vaccine type for prime regime and booster, and underlying disease; (3) effectiveness of heterologous booster and homologous booster for SARS-CoV-2 vaccines: vaccine effectiveness (VE) for prevention of adverse outcomes, including SARS-CoV-2 infection, symptomatic COVID-19, emergency department and urgent care admissions, COVID-19 hospital admissions, COVID-19 ICU admissions, and COVID-19-related death; (4) safety of heterologous booster and homologous booster for SARS-CoV-2 vaccines: number or proportion of cases that had systematic and injection site adverse reaction after vaccination of booster and follow-up period; and (5) immunogenicity of heterologous booster and homologous booster for SARS-CoV-2 vaccines: geometric mean neutralizing titers (GMTs) against different SARS-CoV-2 variants and response rate of antibody and interferon.

Data extraction was conducted by two investigators (DJ and MYR) independently following the criteria above, while discrepancies were solved by consensus or with a third investigator (LQ).

2.3. Quality Assessment

We used the Newcastle-Ottawa quality assessment scale to evaluate the risk of bias of cohort studies and case-control studies and Cochrane Collaboration’s tool for RCTs. Cohort studies and case-control studies were classified as having low (≥7 stars), moderate (5–6 stars), and high risk of bias (≤4 stars) with an overall quality score of 9 stars. RCTs were classified as low, unclear, or high risk of bias from comprehensive evaluation from 7 dimensions, including random sequence generation, allocation concealment, blinding of participants and personnel, incomplete outcome data, selective reporting, and other bias.
Quality assessment was conducted by two investigators (DJ and MYR) independently, while discrepancies were solved by consensus or with a third investigator (LQ).

2.4. Data Synthesis and Statistical Analysis

We performed a meta-analysis to estimate the VE and its 95% confidence interval (CI) against adverse outcomes and odds ratio (OR) and its 95% CI of the safety events after vaccination of heterologous booster and homologous booster for SARS-CoV-2 vaccines. We also estimated the standard mean difference (SMD) and its 95% CI of GMTs against different SARS-CoV-2 variants and OR and its 95% CI of response rate for antibody and interferon. We performed subgroup analyses by article type (preprint article or published article), study design (cohort study, case-control study, or RCTs), and immune condition. For example, inactivated vaccine × 2 + mRNA vaccine × 1 meant 2 primary doses of inactivated vaccines and a booster dose of mRNA vaccine.

Random-effects or fixed-effects models were used to pool the rates and adjusted estimates across studies separately, based on the heterogeneity between estimates ($I^2$). Fixed-effects models would be used if $I^2 \leq 50\%$, which represents low to moderate heterogeneity, and random-effects models would be used if $I^2 \geq 50\%$, representing substantial heterogeneity. The D-L method was used to estimate the tau square in cases of random-effects models. Publication bias was assessed by Harbord’s modified test. All analyses used Stata version 16.0 (Stata Corp, College Station, TX, USA).

3. Results

3.1. Basic Characteristics

In the initial literature research, 779 potential articles were identified up to 27 April 2022, including 424 published articles (118 in PubMed, 153 in Embase, 153 in Web of Science) and 355 preprint articles (140 in Biorxiv, 215 in Medrxiv). A total of 256 duplicates was excluded. After reading the titles and abstracts, 402 articles were excluded based on the inclusion and exclusion criteria. Among the 121 studies under full-text review, 98 studies were excluded. Eventually, 23 studies (including 13 published articles and 10 preprints) were included in this meta-analysis based on the inclusion criteria [14,24–45]. The literature retrieval flow chart is shown in Figure 1.

![Figure 1. Flowchart of the study selection.](image-url)
Of the 23 studies included, 9 were cohort studies, 11 were clinical trials, 2 were case-control studies, and 1 could not be determined. The included studies described or compared the effectiveness and safety of heterologous booster doses with homologous booster doses for SARS-CoV-2 vaccines and involved 1,726,506 inoculation cases of homologous booster dose and 5,343,580 inoculation cases of heterologous booster dose. The characteristics of the included studies are shown in Supplementary Table S1.

3.2. Comparison of Safety between Heterologous Booster and Homologous Booster

We evaluated the systematic adverse reactions with 7 and 28 days after boosting, as well as the injection site adverse reactions with 7 days after boosting. Compared with homologous booster group, there was a higher risk of fever (OR = 1.930, 95% CI, 1.199–3.107), myalgia (OR = 1.825, 95% CI, 1.079–3.089), and malaise or fatigue (OR = 1.745, 95% CI, 1.047–2.906) within 7 days after boosting, and a higher risk of malaise or fatigue (OR = 4.140, 95% CI, 1.729–9.916) within 28 days after boosting in the heterologous booster group (p-value < 0.05). No differences in other systematic or injection site adverse reactions were observed between the homologous and heterologous booster groups. The analysis results are shown in Table 1.

Table 1. Comparison of safety between heterologous booster and homologous booster.

| Safety Events | Number of Data Source | Heterologous Booster (n/N) | Homologous Booster (n/N) | OR  | 95% CI      | p-Value | Weight (%) | I² | P-Heterogeneity |
|---------------|------------------------|---------------------------|--------------------------|-----|-------------|---------|------------|----|----------------|
| Systematic Adverse Reaction (within 7 Days after Boosting) | | | | | | | | | |
| Malaise or fatigue | 13 | 677/1913 | 421/1645 | 1.745 | 1.047–2.906 | <0.05 | 100 | 79.70% | <0.05 |
| Chills | 9 | 455/1737 | 182/1155 | 1.428 | 0.808–2.524 | >0.05 | 100 | 82.60% | <0.05 |
| Fever | 15 | 351/2861 | 126/2227 | 1.930 | 1.199–3.107 | <0.05 | 100 | 59.30% | <0.05 |
| Headache | 15 | 893/2861 | 454/2227 | 1.418 | 0.940–2.140 | >0.05 | 100 | 81.50% | <0.05 |
| Nausea | 11 | 159/1775 | 100/1536 | 1.114 | 0.788–1.574 | >0.05 | 100 | 16.30% | >0.05 |
| Vomiting | 3 | 2/945 | 1/965 | 2.02 | 0.183–22.318 | >0.05 | 100 | - | - |
| Abdominal pain | 2 | 2/169 | 0/128 | 2.518 | 0.258–24.563 | >0.05 | 100 | 0.00% | >0.05 |
| Diarrhea | 7 | 34/1253 | 16/1160 | 1.522 | 0.758–3.055 | >0.05 | 100 | 0 | >0.05 |
| Arthralgia | 8 | 179/1685 | 123/1477 | 1.055 | 0.644–1.730 | >0.05 | 100 | 55.30% | <0.05 |
| Myalgia | 15 | 884/2861 | 401/2227 | 1.825 | 1.079–3.089 | <0.05 | 100 | 88.10% | <0.05 |
| Skin rash | 2 | 5/138 | 2/109 | 1.734 | 0.329–9.144 | >0.05 | 100 | - | - |
| Dizziness | 2 | 7/936 | 4/944 | 1.597 | 0.261–9.786 | >0.05 | 100 | 38.10% | >0.05 |
| Serious adverse events (SAE) | 2 | 0/145 | 0/119 | - | - | - | - | - |
| Systematic Adverse Reaction (within 28 Days after Boosting) | | | | | | | | | |
| Arthralgia | 2 | 14/123 | 9/130 | 2.084 | 0.741–5.866 | >0.05 | 100 | 0.00% | >0.05 |
| Malaise or fatigue | 2 | 32/123 | 16/130 | 4.140 | 1.729–9.916 | <0.05 | 100 | 0.00% | >0.05 |
| Myalgia | 2 | 16/123 | 9/130 | 2.694 | 0.953–7.614 | >0.05 | 100 | 0.00% | >0.05 |
Table 1. Cont.

| Safety Events | Number of Data Source | Heterologous Booster (n/N) | Homologous Booster (n/N) | OR | 95% CI | p-Value | Weight (%) | I² | P-Heterogeneity |
|---------------|-----------------------|---------------------------|--------------------------|----|--------|---------|------------|----|----------------|
| Injection Site Adverse Reaction (within 7 Days after Boosting) | 6 | 125599/155621 | 102419/142630 | 1.053 | 0.535–2.070 | >0.05 | 100 | 84.80% | <0.05 |
| Erythema or redness | 7 | 48/1556 | 47/1391 | 0.806 | 0.420–1.548 | >0.05 | 100 | 37.60% | >0.05 |
| Induration or swelling | 7 | 93/1556 | 79/1389 | 0.802 | 0.385–1.670 | >0.05 | 100 | 65.90% | <0.05 |

3.3. Comparison of Immunogenicity between Heterologous Booster and Homologous Booster

We evaluated the GMTs of neutralizing antibody for different SARS-CoV-2 variants and response rate of antibody and gamma interferon. Compared with homologous booster group, GMTs of anti-RBD IgG (SMD = 1.244, 95% CI, 0.900–1.588) at 14 days were higher after boosting in the heterologous booster group. Compared with the homologous booster group, GMTs of anti-wild-type neutralizing antibody at 14 and 28 days after boosting (SMD = 1.028, 95% CI, 0.654–1.402; SMD = 0.967, 95% CI, 0.571–1.363), and GMTs of anti-Delta neutralizing antibody at 14 days after boosting (SMD = 0.833, 95% CI, 0.509–1.157) were higher in the heterologous booster group (p-value < 0.05).

Compared with the homologous booster group, there was higher response rate of anti-spike IgG at 28 days after boosting (OR = 5.536, 95% CI, 2.738–11.195) and gamma interferon at 14 days after boosting in patients who were negative in baseline (OR = 16.3, 95% CI, 3.439–77.272) in the heterologous booster group (p-value < 0.05). No differences for response rate of neutralizing antibody nearly one month after boosting were observed between the homologous and the heterologous booster groups. The analysis results are shown in Table 2.

Table 2. Comparison of immunogenicity between heterologous booster and homologous booster.

| Index | Number of Study | Heterologous Booster (n/N) | Homologous Booster (n/N) | Effect (SMD) | 95% CI | p-Value | Weight (%) | I² | P-Heterogeneity |
|-------|----------------|---------------------------|--------------------------|--------------|--------|---------|------------|----|----------------|
| GMT of Neutralizing Antibody for VOCs | | | | | | | | | |
| Anti-RBD IgG (14 days After Boosting) | 8 | 1124 | 1067 | 1.244 | 0.900–1.588 | 0 | <0.05 | 100 | 90.90% | 0 | <0.05 |
| GMT of Neutralizing Antibody for VOCs | | | | | | | | | |
| Anti-wild-type (14 days after boosting) | 4 | 295 | 303 | 1.028 | 0.654–1.402 | 0 | <0.05 | 100 | 77.90% | 0.004 | <0.05 |
| Anti-wild-type (28 days after boosting) | 4 | 206 | 212 | 0.967 | 0.571–1.363 | 0 | <0.05 | 100 | 67.90% | 0.025 | <0.05 |
| Anti-Delta (14 days after boosting) | 4 | 295 | 303 | 0.833 | 0.509–1.157 | 0 | <0.05 | 100 | 71.80% | 0.014 | <0.05 |
| response rate of anti-spike IgG (28 days after boosting) | 2 | 264/321 | 115/205 | 5.536 | 2.738–11.195 | 0 | <0.05 | 100% | 0 | 0.495 | >0.05 |
### Table 2. Cont.

| Index | Number of Data Source | Heterologous Booster (n/N) | Homologous Booster (n/N) | OR | 95% CI | p-Value | Weight (%) | I2 | P-Heterogeneity |
|-------|-----------------------|-----------------------------|--------------------------|----|--------|---------|------------|----|----------------|
|       |                       |                             |                          |    |        |         |            |    |                |
|       | **Response Rate of Antibody** |                               |                          |    |        |         |            |    |                |
|       | response rate of neutralizing antibody (nearly 1 month after boosting) | 4                           | 160/289                  | 93/234 | 1.446 | 0.864–2.422 | 0.161 | >0.05 | 100% | 0.49 | >0.05 |
|       | response rate of gamma interferon (14 days after boosting in patients who were negative in baseline) | 4                           | 54/87                    | 2/18 | 16.3 | 3.439–77.272 | 0  | <0.05 | 100% | 0.321 | >0.05 |
|       | **Response Rate of T cell** |                               |                          |    |        |         |            |    |                |
|       |                                                                   |                            |                          |    |        |         |            |    |                |

### 3.4. Comparison of Vaccine Effectiveness between Heterologous Booster and Homologous Booster

In the homologous booster group, the pooled VE was 84.00% (95% CI, 82.8–85.1%) for the prevention of SARS-CoV-2 infection, 17.30% (95% CI, 14.4–20.2%) for the prevention of symptomatic COVID-19, 82.70% (95% CI, 81.7–83.7%) for the prevention of emergency department and urgent care admissions, 93.20% (95% CI, 92.4–94.0%) for the prevention of COVID-19 hospital admissions.

In the heterologous booster group, the pooled VE was 96.10% (95% CI, 95.8–96.3%) for the prevention of SARS-CoV-2 infection, 56.80% (95% CI, 56.3–57.4%) for the prevention of symptomatic COVID-19, 97.40% (95% CI, 97.1–97.7%) for the prevention of COVID-19 hospital admissions, 98.70% (95% CI, 98.4–99.1%) for the prevention of COVID-19 ICU admissions and 98.00% (95% CI, 97.4–98.6%) for the prevention of COVID-19-related death.

The analysis results are shown in Table 3, which suggests that the vaccine effectiveness of the heterologous booster for the prevention of SARS-CoV-2 infection, symptomatic COVID-19, and COVID-19-related hospital admissions was higher than the homologous booster.

### Table 3. Comparison of effectiveness between heterologous booster and homologous booster.

| Homologous Booster Dose | Outcomes | No. of Studies | Vaccine Effectiveness (%) | 95% CI | I2 | P-Heterogeneity | p Value for Subgroup Differences | Weight (%) |
|-------------------------|----------|----------------|---------------------------|--------|----|-----------------|-------------------------------|------------|
|                         | Prevention of SARS-CoV-2 Infection | Published | 3 | 85.80% | 84.3–87.2% | 98.30% | 0 | 0 | 66.51 |
|                         |          | Preprint | 5 | 80.50% | 78.4–82.5% | 92.90% | 0 | 0 | 33.49 |
|                         | Study design | Cohort study | 7 | 83.30% | 82.1–84.5% | 96.60% | 0 | 0 | 92.84 |
|                         | RCT | 1 | 92.40% | 88.1–96.7% | - | - | 0 | 7.16 |
|                         | Immune condition | mRNA vaccine ×3 | 6 | 86.40% | 84.8–88.0% | 96.50% | 0 | 0 | 55.29 |
|                         | inactivated vaccine ×3 | 1 | 78.80% | 76.9–80.7% | - | - | 0 | 37.55 |
|                         | SOBERANA ×2 + SOBERANA plus ×1 | 1 | 92.40% | 88.1–96.7% | - | - | 0 | 7.16 |
|                         | Overall | 8 | 84.00% | 82.8–85.1% | 96.40% | 0 | 0 | 100 |

Int. J. Environ. Res. Public Health 2022, 19, 10752
7 of 17
Table 3. Cont.

### Homologous Booster Dose

| Outcomes | No. of Studies | Vaccine Effectiveness (%) | 95% CI | I² | P-Value for Subgroup Differences | Weight (%) |
|----------|----------------|--------------------------|--------|----|----------------------------------|------------|
| **Prevention of Symptomatic COVID-19** |                |                          |        |    |                                  |            |
| Article type |                |                          |        |    |                                  |            |
| Published | 1              | 75.50%                   | 60.4–90.6% | -  | -                               | 0          | 96.2                     |
| Preprint  | 1              | 15%                      | 12–18%  | -  | -                               | 0          | 3.8                      |
| Overall   | 2              | 17.30%                   | 14.4–20.2% | 98.30% | 0 | 0 | 100                 |
| **Prevention of Emergency Department and Urgent Care Admissions** |                |                          |        |    |                                  |            |
| Immune condition |                |                          |        |    |                                  |            |
| mRNA vaccine ×3 | 1 | 83.00%                   | 82.0–83.7% | -  | -                               | 0          | 99.1                     |
| adenosivus vector vaccine ×2 | 1 | 54.00%                   | 44.0–64.0% | -  | -                               | 0          | 0.99                     |
| Overall   | 2              | 82.70%                   | 81.7–83.7% | 96.90% | 0 | 0 | 100                 |
| **Prevention of COVID-19 Hospital Admissions** |                |                          |        |    |                                  |            |
| Article type |                |                          |        |    |                                  |            |
| published   | 3              | 88.70%                   | 87.5–90.0% | 89.10% | 0 | 0 | 38.44                    |
| preprint    | 1              | 93.20%                   | 92.4–94.0% | -  | -                               | 0          | 61.56                    |
| Immune condition |                |                          |        |    |                                  |            |
| mRNA vaccine ×3 | 2 | 94.20%                   | 93.3–95.0% | 97.60% | 0 | 0 | 88.92                     |
| inactivated vaccine ×3 | 1 | 86.30%                   | 83.9–88.7  | -  | -                               | 0          | 10.69                    |
| adenosivus vector vaccine ×2 | 1 | 67.00%                   | 54.5–79.5% | -  | -                               | 0          | 0.39                     |
| Overall   | 4              | 93.20%                   | 92.4–94.0% | 96.90% | 0 | 0 | 100                 |

### Heterologous Booster Dose

| Outcomes | No. of Studies | Vaccine Effectiveness (%) | 95% CI | I² | P-Value for Subgroup Differences | Weight (%) |
|----------|----------------|--------------------------|--------|----|----------------------------------|------------|
| **Prevention of SARS-CoV-2 Infection** |                |                          |        |    |                                  |            |
| Immune condition |                |                          |        |    |                                  |            |
| adenovirus vector vaccine ×1 + mRNA vaccine ×1 | 2 | 90.70%                   | 89.1–92.2% | 5.60% | 0.303 | 0 | 2.42                     |
| inactivated vaccine ×2 + recombinant vaccine ×1 | 1 | 93.20%                   | 92.4–94.0% | -  | -                               | 0          | 8.68                     |
| inactivated vaccine ×2 + mRNA vaccine ×1 | 1 | 96.50%                   | 96.2–96.7% | -  | -                               | 0          | 88.9                     |
| Overall   | 4              | 96.10%                   | 95.8%–96.3% | 97.30% | 0 | 0 | 100                 |
| **Prevention of Symptomatic COVID-19** |                |                          |        |    |                                  |            |
| Article type |                |                          |        |    |                                  |            |
| Published   | 1              | 71.40%                   | 49.3–93.5% | -  | -                               | 0          | 0.06                     |
| Preprint    | 1              | 56.80%                   | 56.3–57.4% | -  | -                               | 0          | 99.94                    |
| Immune condition |                |                          |        |    |                                  |            |
| adenovirus vector vaccine ×2 + mRNA vaccine ×1 | 1 | 71.40%                   | 49.3–93.5% | -  | -                               | 0          | 0.06                     |
| inactivated vaccine ×2 + recombinant vaccine ×1 | 1 | 56.80%                   | 56.3–57.4% | -  | -                               | 0          | 99.94                    |
| Overall   | 2              | 56.80%                   | 56.3–57.4% | 40.30% | 0.196 | 0 | 100                 |
| **Prevention of COVID-19 Hospital Admissions** |                |                          |        |    |                                  |            |
| Immune condition |                |                          |        |    |                                  |            |
| adenovirus vector vaccine ×1 + mRNA vaccine ×1 | 1 | 78.00%                   | 71.0–85.0% | -  | -                               | 0          | 0.21                     |
| inactivated vaccine ×2 + mRNA vaccine ×1 | 1 | 96.10%                   | 96.3–96.9% | -  | -                               | 0          | 16.03                    |
| inactivated vaccine ×2 + recombinant vaccine ×1 | 1 | 97.40%                   | 97.3–98.1% | -  | -                               | 0          | 83.76                    |
| Overall   | 3              | 97.40%                   | 97.1–97.7% | 95.30% | 0 | 0 | 100                 |
3.5. Quality Evaluation and Publication Bias

We evaluated the quality of the included cohort studies and case-control studies according to the Newcastle-Ottawa quality assessment scale, all of them were of good quality and had a low risk of bias (≥7 stars), as shown in Tables 4 and 5. The Cochrane Collaboration’s tool was used to assess the risk of bias of the included RCTs, and the results suggested that most of the studies were at low risk of bias, followed by unclear risk of bias, as shown in Figure 2.

| Outcomes                          | No. of Studies | Vaccine Effectiveness (%) | 95% CI          | I²   | p-Value for Subgroup Differences | Weight (%) |
|-----------------------------------|----------------|--------------------------|-----------------|------|---------------------------------|------------|
| **Prevention of COVID-19 ICU Admissions** |                |                          |                 |      |                                 |            |
| Immune condition                  |                |                          |                 |      |                                 |            |
| inactivated vaccine ×2 + mRNA vaccine ×1 | 1              | 96.20%                   | 94.9–97.6%      | -    | -                               | 6.3        |
| inactivated vaccine ×2 + recombinant vaccine ×1 | 1              | 98.90%                   | 98.6–99.3%      | -    | -                               | 93.7       |
| Overall                           | 2              | 98.70%                   | 98.4–99.1%      | 93.10% | 0                               | 100        |
| **Prevention of COVID-19-Related Death** |                |                          |                 |      |                                 |            |
| Immune condition                  |                |                          |                 |      |                                 |            |
| inactivated vaccine ×2 + mRNA vaccine ×1 | 1              | 96.80%                   | 94.5–99.1%      | -    | -                               | 7.7        |
| inactivated vaccine ×2 + recombinant vaccine ×1 | 1              | 98.10%                   | 97.5–98.8%      | -    | -                               | 92.3       |
| Overall                           | 2              | 98.00%                   | 97.4–98.6%      | 15.50% | 1.277                           | 100        |
### Table 4. Risk of bias and quality assessment by Newcastle-Ottawa quality assessment scale (NOS) of the included cohort studies.

| First Author (Published Time) | Selection | Comparability | Outcome |
|-------------------------------|-----------|---------------|---------|
| | Representativeness of the Exposed Cohort | Selection of the Non-Exposed Cohort | Ascertainment of Exposure | Demonstration that Outcome of Interest Was Not Present at Start of Study | Comparability of Cohorts on the Basis of the Design or Analysis | Assessment of Outcome | Was Follow-Up Long Enough for Outcomes to Occur | Adequacy of Follow-Up of Cohorts | Number of Stars | Risk of Bias |
|---|---|---|---|---|---|---|---|---|---|---|
| Ai, J. et al., 2022 [25] | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 7 | Low |
| Natarajan, K. et al., 2022 [28] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Jara, A. et al., 2022 [29] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Menni, C. et al. 2022 [32] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Khong, K. W. et al., 2022 [33] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Çağlayan, D. et al., 2022 [34] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Angkasekwinai, N. et al., 2022 [38] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 8 | Low |
| Mok, C. K. P. et al., 2022 [39] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Starrfelt, J. et al., 2022 [36] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |
| Baum, U. et al., 2022 [44] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 | Low |

### Table 5. Risk of bias and quality assessment by Newcastle-Ottawa quality assessment scale (NOS) of the included case-control studies.

| First Author (Published Time) | Selection | Comparability | Exposure |
|-------------------------------|-----------|---------------|----------|
| | Is the Case Definition Adequate? | Representativeness of the Cases | Selection of Controls | Definition of Controls | Comparability of Cases and Controls on the Basis of the Design or Analysis | Ascertainment of Exposure | Same Method of Ascertainment for Cases and Controls | Non-Response Rate | Number of Stars | Risk of Bias |
|---|---|---|---|---|---|---|---|---|---|---|
| Ranzani, Otavio T. et al., 2022 [42] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 | Low |
| Andrews, N. et al., 2022 [43] | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 | Low |
4. Discussion

For now, vaccination campaigns remain key to mitigating the wave of COVID-19, helping to prevent COVID-19-related severe illness and death, and helping to prevent health burden events, such as long-COVID-19 sequelae. However, after a period of vaccination, there are some weakened immunities, but there are protective effects, such as the booster vaccination can provide a double-growth decline in antibodies and can better deal with mutant strains. Therefore, it is of great significance to strengthen immunization for key and susceptible populations. Heterologous vaccination has become as important as homologous vaccination in enhancing immunization. The difference of safety and effectiveness between the two has attracted people’s attention.

Our systematic review and meta-analysis of 23 studies, involving 1,726,506 inoculation cases of homologous booster doses and 5,343,580 inoculation cases of heterologous booster doses, provided VE for homologous and heterologous vaccines against adverse outcomes.
of COVID-19 and performed a subgroup analysis to compare the differences based on prime-booster regime, study design, and article type. At the same time, we also provided the OR of safety events of homologous and heterologous vaccination groups, as well as the comparison of immunogenicity. Different from previous study that compared the effectiveness of homologous and heterologous booster for SARS-CoV-2 vaccines [13], we also focused on safety and immunogenicity and conducted a more in-depth study on the differences between the two groups.

Available data showed that the homologous and heterologous boosters of SARS-CoV-2 vaccines provided a high level of protection against COVID-19 for individuals with a complete primary regimen for COVID-19 vaccine. Heterologous booster showed higher VE than homologous booster vaccination in the prevention of SARS-CoV-2 infection (96.1% vs. 84%), symptomatic COVID-19 (56.8% vs. 17.3%), and COVID-19 hospital admissions (97.4% vs. 93.2%). We observed that a mRNA booster or a recombinant booster after two inactivated vaccines both showed superior effectiveness over other heterologous vaccination regimes in preventing COVID-19 admissions, COVID-19 ICU admissions, and COVID-19-related death, with VE higher than 95%. Our results was consistent with those of a large-scale prospective cohort study [29], it showed that the VE in preventing symptomatic COVID-19 was 78.8% for the homologous booster group (three-dose CoronaVac), 96.5% for primary series (two-dose CoronaVac) with a BNT162b2 booster, and 93.2% for primary series with a AZD1222 booster. Additionally, the VE in preventing COVID-19 hospital admissions, COVID-19 ICU admissions, and COVID-19-related death was 86.3%, 92.2%, and 86.7% for the homologous booster, 96.1%, 96.2%, and 96.8% for a BNT162b2 booster, and 97.7%, 98.9%, and 98.1% for an AZD1222 booster. For all outcomes, a heterologous booster showed higher VE than a homologous booster.

The high VE by the heterologous booster may be related to levels of antibody titer and T-cell responses. A study of Turkish healthcare workers showed, in the heterologous booster group (two-dose CoronaVac with a BNT162b2 booster), median antibody levels at four months after the second dose of CoronaVac and at 7–67 days after third dose were 168 AU/mL and 17,609 AU/mL, respectively, with a 104.8-fold increase; for the homologous booster group (three-dose CoronaVac), the median antibody levels were 141.1 AU/mL and 1237.9 AU/mL, respectively, with an 8.7-fold increase. Compared with homologous booster group, a 14.2-fold increase was detected in the BNT162b2 booster group [34]. The results of a phase 4 randomized trial showed that neutralizing antibody against wild-type SARS-CoV-2 was from 2.5 at 0 day before booster vaccination to 197.4 at 14 days after vaccination in the heterologous booster group (two-dose CoronaVac with a Concidecia booster) and from 2.2 at 0 day before booster vaccination to 33.6 at 14 days after vaccination in the homologous booster group (three-dose CoronaVac). Although GMTs of neutralizing antibody was decreased slightly in both groups at 28 days after boosting, in the heterologous booster group it was still significantly higher than that in the homologous booster group [14]. Our study showed that the heterologous booster group has not only a higher level of neutralizing antibody but also a higher level of T-cell response rate than that in the homologous booster group, which was consistent with the results of Roos S G Sablerolles et al. They assessed the T-cell response based on the levels of Interferon-γ and found the heterologous booster group (one-dose Ad26.COV2.S with a mRNA-1273 or BNT162b2 booster) induced higher levels of T-cell response than the homologous group (91.7%, 91.5% vs. 72.7%) [30]. Available data showed that both the homologous and heterologous boosters induced systemic and injection site adverse reactions. The heterologous booster group had a higher risk of partial systemic adverse reactions. No serious adverse events were observed in the homologous and heterologous booster groups in our study. Previous studies showed that these adverse events could be resolved in short period [30,46]. Toshio Naito found that most adverse reactions were mild to moderate and could be resolved within one week with no sequelae in people who received a BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 [46]. In addition, the incidence of adverse reactions tended to decrease in those
Roos S.G. Sablerolles found that adverse events within 7 days after booster vaccination were mild to moderate, with symptoms generally resolved within 48 h [30].

**Differences in Effectiveness between Homologous and Heterologous Boosters for SARS-CoV-2 Variants**

The VE was higher in a complete primary regimen with a booster group in preventing COVID-19 hospital admissions caused by Omicron variants than a primary regimen only group [47]. A study from Israel showed that a third dose of the mRNA vaccine significantly reduced the rate of confirmed SARS-CoV-2 infection and severe COVID-19 illness [48]. Numerous studies also provided clear serological evidence. Vaccination with a booster can induce the level of antibody concentrations against different variants of SARS-CoV-2, and optimum concentration of antibodies can provide significant protection against infection from variants [49]. A study conducted among people who were aged ≥18 years with a previous positive nucleic acid amplification test (NAAT) or diagnosis of COVID-19 found the VE in preventing COVID-19 hospital admissions was 57.8% during Delta-predominant period and 67.6% during Omicron-predominant period [50]. In a slightly different way, the results of another study showed a higher effectiveness after booster vaccination during the Delta period compared with the Omicron period (70% vs. 54%) [51]. A previous study showed that both the homologous booster and the heterologous boosters have better protection against COVID-19 hospitalizations caused by Omicron variant where VE was 77% in mRNA1273 homologous series and 30% in AD25. In COV2 homologous series, VE was 64% in the heterologous booster group (one-dose Johnson with a mRNA vaccine booster) [47]. A systematic review showed that a third dose of vaccine led to a significant increase in serum neutralization of Omicron variants in both heterologous and homologous booster groups. Neutralizing titers against the Omicron variant increased by 1.17 to 96.94 folds in the homologous booster group, while the wild-type, alpha, beta, and delta variants increased by 1.85 to 53.83, 3.15, 2.94 to 119.84, and 1.80 to 53.81, respectively. Similarly, neutralization titers for Omicron variants, wild-type, alpha, beta, and delta variants were found to increase by 2 to 15.87, 18.4 to 36.1, 17.4 to 89.22, and 27.9 to 42.80, respectively, in the heterologous booster group [52]. Additionally, Ai and his colleagues found that Omicron might more likely escape vaccine-induced immune protection after a third heterologous booster of protein subunit vaccine (ZF2001) compared to prototypes and other variants of concern [25].

At present, vaccination is still the key to control the epidemic. Booster vaccination can help prevent COVID-19-related severe illness and death and has good protection against different SARS-CoV-2 variants. Heterologous boosted vaccination provides an alternative to enhanced immunogenicity and is a process of improving immunization strategies. There are still few original studies on the effectiveness and safety of homologous and heterologous boosters of SARS-CoV-2 vaccines, and more relevant evidence is needed in the future to continuously improve immunization strategies.

Our study has some limitations. First, the small number, different study designs, and different time frames of included articles in which vaccine effectiveness was calculated, resulted in large confidence intervals and lack of accuracy of some outcomes. Second, the I² of some outcomes were large, which may be caused by the difference in age and sex ratio of the study population. Third, although available data showed that the heterologous booster group had stronger immunogenicity than that of the homologous vaccinated group, due to limited data, the GMTs level of only part of the variants was analyzed. Fourth, we analyzed data 14 days after the booster vaccination mainly, data for longer periods, such as 28 days after booster vaccination or longer, were limited, which could not fully explain the difference in immunogenicity between the homologous and heterologous vaccination groups. Fifth, in the original study design, we sought to perform subgroup analysis of the effectiveness of the homologous and heterologous boosters of different age group recipients, but due to the limited data, we could not do so. Sixth, a significant number of the included participants were primarily immunized with two doses of inactivated vaccine and boosted
with mRNA or other technology; however, evidence on advantages in terms of effectiveness for other regimens was still limited. For the third limitation, we made some supplements in the discussion.

5. Conclusions

Our results suggested homologous and heterologous booster of SARS-CoV-2 vaccines provided high VE in preventing SARS-CoV-2 infection, COVID-19 hospital admissions, COVID-19 ICU admissions, and COVID-19-related death. The heterologous booster showed higher VE than the homologous booster in the prevention of SARS-CoV-2 infection, symptomatic COVID-19, and COVID-19 hospital admissions. Compared with the homologous booster group, there was a higher risk of fever, myalgia, and malaise or fatigue within 7 days after boosting and a higher risk of malaise or fatigue within 28 days after boosting in the heterologous booster group. Our findings suggested that both the homologous and heterologous COVID-19 booster doses had great effectiveness, immunogenicity, and acceptable safety, and a heterologous booster dose was more effective, which would help make appropriate public health decisions, reduce public hesitancy in vaccination, and promote rational allocation of COVID-19 vaccine resources.

Supplementary Materials: The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijerph191710752/s1, PRISMA 2020 checklist; Table S1: Characteristics of the included studies.

Author Contributions: J.D. and Y.M. contributed equally as first authors. J.L. and M.L. contributed equally as correspondence authors. J.L. and M.L. conceived and designed the study. J.D., Y.M. and Q.L. carried out the literature searches, extracted the data, and assessed the study quality. J.D. and Y.M. performed the statistical analysis and wrote the manuscript. J.L., M.L., Q.L., M.D., J.D. and Y.M. revised the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding: This study was funded by the National Natural Science Foundation of China (72122001; 71934002), National R&D Key project (2021ZD0114101, 2021ZD0114104, 2021ZD0114105), and National Science and Technology Project on Development Assistance for Technology, Developing China-ASEAN Public Health Research and Development Collaborating Center (No. KY202101004). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the paper. No payment was received by any of the co-authors for the preparation of this article.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data are available from the corresponding author by request.

Conflicts of Interest: The authors have no competing interest to declare.

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| SARS-CoV-2    | severe acute respiratory syndrome coronavirus 2 |
| COVID-19      | coronavirus disease 2019 |
| VE            | vaccine effectiveness |
| CI            | confidence interval |
| OR            | odds ratios |
| ICU           | intensive care unit |
| GMTs          | geometric mean neutralizing titers |
| SMD           | standard mean difference |
| PRISMA        | preferred reporting items for systematic reviews and meta-analyses |
| WHO           | World Health Organization |
| rt-PCR        | reverse-transcription polymerase chain reaction |
| RCTs          | randomized controlled trial |
| NAAT          | nucleic acid amplification test |
References

1. Akande, O.W.; Akande, T.M. COVID-19 pandemic: A global health burden. Niger. Postgrad. Med. J. 2020, 27, 147–155. [CrossRef] [PubMed]
2. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022. Available online: https://covid19.who.int (accessed on 10 July 2022).
3. World Health Organization. Coronavirus Disease (COVID-19): Vaccines. 2022. Available online: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-vaccines (accessed on 10 July 2022).
4. World Health Organization. WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination. 2022. Available online: https://www.who.int/news/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination (accessed on 10 July 2022).
5. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2022. Available online: https://covid19.who.int (accessed on 10 July 2022).
6. World Health Organization. Strategy to Achieve Global COVID-19 Vaccination by Mid-2022. Available online: https://www.who.int/publications/i/item/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022 (accessed on 10 July 2022).
7. Feikin, D.R.; Higdon, M.M.; Abu-Raddad, L.J.; Andrews, N.; Araos, R.; Goldberg, Y.; Groome, M.; Huppert, A.; O’Brien, K.; Smith, P.G.; et al. Duration of effectiveness of vaccines against SARS-CoV-2 infection and COVID-19 disease: Results of a systematic review and meta-regression. Lancet 2022, 399, 924–944. [CrossRef]
8. World Health Organization. Interim Statement on Booster Doses for COVID-19 Vaccination. 2022. Available online: https://www.who.int/news/item/22-12-2021-interim-statement-on-booster-doses-for-covid-19-vaccination---update-22-december-2021 (accessed on 10 July 2022).
9. Krause, P.R.; Fleming, T.R.; Peto, R.; Longini, I.M.; Figueroa, J.P.; Sterne, J.A.C.; Cravioto, A.; Rees, H.; Higgins, J.P.T.; Boutron, I.; et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet 2021, 398, 1377–1380. [CrossRef]
10. World Health Organization. WHO SAGE Values Framework for the Allocation and Prioritization of COVID-19 Vaccination. 2022. Available online: https://www.who.int/publications/i/item/who-sage-values-framework-for-the-allocation-and-prioritization-of-covid-19-vaccination (accessed on 10 July 2022).
11. Chiu, N.C.; Chi, H.; Tu, Y.K.; Huang, Y.N.; Tai, Y.L.; Weng, S.L.; Chang, L.; Huang, D.T.N.; Huang, F.Y.; Lin, C.Y. To mix or not to mix? A rapid systematic review of heterologous prime-boost covid-19 vaccination. Expert Rev. Vaccines 2021, 20, 1211–1220. [CrossRef]
12. World Health Organization. Interim Recommendations for Heterologous COVID-19 Vaccine Schedules. Available online: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-heterologous-schedules (accessed on 10 July 2022).
13. Au, W.Y.; Cheung, P.P.H. Effectiveness of heterologous and homologous COVID-19 vaccine regimens: Living systematic review with network meta-analysis. Br. Med. J. Clin. Res. Ed. 2022, 377, e069989. [CrossRef]
14. Li, J.; Hou, L.; Guo, X.; Jin, P.; Wu, S.; Zhu, J.; Pan, H.; Wang, X.; Song, Z.; Wan, J.; et al. Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac Vaccine: A randomized phase 4 trial. Nat. Med. 2022, 28, 401–409. [CrossRef]
15. Li, J.X.; Wu, S.P.; Guo, X.L.; Tang, R.; Huang, B.Y.; Chen, X.Q.; Chen, Y.; Hou, L.H.; Liu, J.X.; Zhong, J.; et al. Safety and immunogenicity of heterologous boost immunisation with an orally administered aerosolised Ad5-nCoV after two-dose priming with an inactivated SARS-CoV-2 vaccine in Chinese adults: A randomised, open-label, single-centre trial. Lancet Respir. Med. 2022, 10, 739–748. [CrossRef]
16. Ai, J.; Zhang, H.; Zhang, Q.; Zhang, Y.; Lin, K.; Fu, Z.; Song, J.; Zhao, Y.; Fan, M.; Wang, H.; et al. Recombinant protein subunit vaccine booster following two-dose inactivated vaccines dramatically enhanced anti-RBD responses and neutralizing titers against SARS-CoV-2 and Variants of Concern. Cell Res. 2022, 32, 103–106. [CrossRef]
17. Zeng, G.; Wu, Q.; Pan, H.; Li, M.; Yang, J.; Wang, L.; Wu, Z.; Jiang, D.; Deng, X.; Chu, K.; et al. Immunogenicity and safety of a third dose of CoronaVacc, and immune persistence of a two-dose schedule, in healthy adults: Interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect. Dis. 2022, 22, 483–495. [CrossRef]
18. Cao, Y.; Hao, X.; Wang, X.; Wu, Q.; Song, R.; Zhao, D.; Song, W.; Wang, Y.; Yisimayi, A.; Wang, W.; et al. Humoral immunogenicity and reactogenicity of CoronaVac or ZF2001 booster after two doses of inactivated vaccine. Cell Res. 2022, 32, 107–109. [CrossRef]
19. Atmar, R.L.; Lyke, K.E.; Deming, M.E.; Jackson, L.A.; Branche, A.R.; Sahly, H.M.E.; Rostad, C.A.; Martin, J.M.; Johnston, C.; Rupp, R.E.; et al. Homologous and Heterologous Covid-19 Booster Vaccinations. N. Engl. J. Med. 2022, 386, 1046–1057. [CrossRef]
20. World Health Organization. Status of COVID-19 Vaccines within WHO EUL/PQ Evaluation Process. 2022. Available online: https://extranet.who.int/pqweb/sites/default/files/documents/Status_COVID_VAX_07July2022.pdf (accessed on 10 July 2022).
21. World Health Organization. WHO Validates 11th Vaccine for COVID-19. 2022. Available online: https://www.who.int/news/item/19-05-2022-who-validates-11th-vaccine-for-covid-19 (accessed on 10 July 2022).
22. World Health Organization. COVID-19 Vaccines with WHO Emergency Use Listing. 2022. Available online: https://extranet.who.int/pqweb/vaccines/vaccinescovid-19-vaccine-eul-issued (accessed on 10 July 2022).
23. Page, M.J.; McKenzie, J.E.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021, 372, n71. [CrossRef]
24. Atmar, R.L.; Lyke, K.E.; Deming, M.E.; Jackson, L.A.; Branche, A.R.; Sahly, H.M.E.; Rostad, C.A.; Martin, J.M.; Johnston, C.; Rupp, R.E.; et al. Heterologous SARS-CoV-2 Booster Vaccinations—Preliminary Report. medRxiv 2021. [CrossRef]

25. Ai, J.; Zhang, H.; Zhang, Y.; Wu, J.; Lin, K.; Zhang, Y.; Wan, Y.; Huang, Y.; Song, J.; Fu, Z.; et al. Omicron variant showed lower neutralizing sensitivity than other SARS-CoV-2 variants to immune sera elicited by vaccines after boost. Emerg. Microbes infect. 2022, 11, 337–343. [CrossRef]

26. Reindl-Schwaighofer, R.; Heinzel, A.; Mayrdorfer, M.; Jabbour, R.; Hofbauer, T.M.; Merrelaar, A.; Eder, M.; Regele, F.; Dobener, K.; Specht, P.; et al. Comparison of SARS-CoV-2 Antibody Response 4 Weeks after Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA Intern. Med. 2022, 182, 165–171. [CrossRef]

27. Clemens, S.A.C.; Wecks, L.; Clemens, R.; Mendes, A.V.A.; Souza, A.R.; Silveira, M.B.V.; da Guarda, S.N.F.; de Nobrega, M.M.; de Moraes Pinto, M.I.; Gonzalez, I.G.S.; et al. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): A phase 4, non-inferiority, single blind, randomised study. Lancet 2022, 399, 521–529. [CrossRef]

28. Natarajan, K.; Prasad, N.; Dascomb, K.; Irving, S.A.; Yang, D.H.; Gaglani, M.; Klein, N.P.; Desilva, M.B.; Ong, T.C.; Grannis, S.J.; et al. Effectiveness of Homologous and Heterologous COVID-19 Booster Doses Following 1 Ad.26.COV2.S [Janssen [Johnson & Johnson] Vaccine Dose against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations among Adults-VISION Network, 10 States, December 2021–March 2022. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 495–502.

29. Jara, A.; Undurraga, E.A.; Zubizarreta, J.R.; Gonzalez, C.; Pizarro, A.; Acevedo, J.; Leo, K.; Paredes, F.; Bralic, T.; Vergara, V.; et al. Effectiveness of homologous and heterologous booster doses for an inactivated SARS-CoV-2 vaccine: A large-scale prospective cohort study. Lancet Glob. Health 2022, 10, e798–e806. [CrossRef]

30. Menni, C.; May, A.; Polidori, L.; Louca, P.; Wolf, J.; Capdevila, J.; Hu, C.; Ourselin, S.; Steves, C.J.; Valdes, A.M.; et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: A prospective community study from the ZOE COVID Study. Lancet Infect. Dis. 2022, 22, 1002–1010. [CrossRef]

31. Khong, K.W.; Liu, D.; Leung, K.Y.; Lu, L.; Lam, H.Y.; Chen, L.; Chan, P.C.; Lam, H.M.; Xie, X.; Zhang, R.; et al. Antibody Response of Combination of BNT162b2 and CoronaVac Platforms of COVID-19 Vaccines against Omicron Variant. Vaccines 2022, 10, 160. [CrossRef] [PubMed]

32. Çağlayan, D.; Sünner, A.F.; Şiyve, N.; Güzel, I.; Irmak, Ç.; Işik, E.; Appak, O.; Celik, M.; Ozturk, G.; Cavus, S.A.; et al. An analysis of antibody response following the second dose of CoronaVac and humoral response after booster dose with BNT162b2 or CoronaVac among healthcare workers in Turkey. J. Med. Virol. 2022, 94, 2212–2221. [CrossRef] [PubMed]

33. Bonelli, M.; Mrak, D.; Tobudic, S.; Sieghart, D.; Mandl, P.; Kornek, B.; Simader, E.; Radner, E.; Perkmann, T.; Haslacher, H. Additional Heterologous versus Homologous Booster Vaccination in Immunosuppressed Patients without SARS-CoV-2 Antibody Serumconversion after Primary mRNA Vaccination: A Randomized Controlled Trial. Arthritis Rheumatol. 2021, 73, 4125–4126. [CrossRef]

34. Starrfelt, J.; Danielsen, A.S.; Buanes, E.A.; Juvet, L.K.; Lyngstad, T.M.; Ro, G.O.I.; Veneti, L.; Meijerink, H. Age and product dependent vaccine effectiveness against SARS-CoV-2 infection and hospitalisation among adults in Norway: A national cohort study, July–November 2021. medRxiv 2022. [CrossRef]

35. Heinzel, A.; Schretzenmeier, E.; Regele, F.; Hu, K.; Raab, L.; Eder, M.; Aigner, C.; Jabbour, R.; Aschauer, C.; Stefanski, A.L.; et al. Three-month follow-up of heterologous vs. homologous third vaccination in kidney transplant recipients. medRxiv 2022. [CrossRef]

36. Angkasekwinai, N.; Niyomnaitham, S.; Sewatanon, J.; Phumiamorn, S.; Sukapirom, K.; Senawong, S.; Toh, Z.Q.; Umrod, P.; Somporn, T.; Chumpol, S.; et al. The immunogenicity and reactogenicity of four COVID-19 booster vaccinations against SARS-CoV-2 variants of concerns (Delta, Beta, and Omicron) following CoronaVac or ChAdOx1 nCoV-19 primary series. medRxiv 2022. [CrossRef]

37. Reindl-Schwaighofer, R.; Heinzel, A.; Mayrdorfer, M.; Jabbour, R.; Hofbauer, T.M.; Merrelaar, A.; Eder, M.; Regele, F.; Dobener, K.; Specht, P.; et al. Comparison of SARS-CoV-2 Antibody Response 4 Weeks after Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients: A Randomized Clinical Trial. JAMA Intern. Med. 2022, 182, 165–171. [CrossRef]

38. Mok, C.K.P.; Cheng, S.M.S.; Chen, C.; You, K.; Chan, T.O.; Lai, K.C.; Ling, K.C.; Sun, Y.; Ho, L.L.; Feiris, M.; et al. A RCT of a third dose CoronaVac or BNT162b2 vaccine in adults with two doses of CoronaVac. medRxiv 2021. [CrossRef]

39. Toledo-Romani, M.E.; Carmenate, M.G.; Silva, C.V.; Rodriguez, W.B.; Perez, M.M.; Gonzalez, M.C.R.; Moreno, B.P.; Hernandez, I.C.M.; Romero, R.G.-M.; Tabio, O.S.; et al. Efficacy and safety of SOBERANA 02, a COVID-19 conjugate vaccine in heterologous three-dose combination. medRxiv 2021. [CrossRef]

40. Zhang, Z.; Wu, S.; Liu, Y.; Li, K.; Fan, P.; Song, X.; Wang, Y.; Zhao, Z.; Zhang, X.; Shang, J.; et al. Aerosolized Ad5-nCoV booster vaccination elicited potent immune response against the SARS-CoV-2 Omicron variant after inactivated COVID-19 vaccine priming. medRxiv 2022. [CrossRef]

41. Ranzani, O.T.; Hitchings, M.D.T.; de Melo, R.L.; de França, G.V.A.; de Fernandes, C.F.R.; Lind, M.L.; Torres, M.S.S.; Tsuha, D.H.; David, L.C.S.; Said, R.F.C.; et al. Effectiveness of an Inactivated COVID-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.1.1.529) Variant. medRxiv 2022. [CrossRef]
43. Andrews, N.; Stowe, J.; Kirsebom, F.; Toffs, S.; Riccardo, T.; Gallagher, E.; Gower, C.; Kall, M.; Groves, N.; O’Connell, A.-M.; et al. Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern. *medRxiv* 2021. [CrossRef]

44. Baum, U.; Poukka, E.; Leino, T.; Kilpi, T.; Nohynek, H.; Palmu, A.A. High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron. *medRxiv* 2022. [CrossRef]

45. Kaabi, N.A.; Yang, Y.K.; Du, L.F.; Xu, K.; Shao, S.; Liang, Y.; Kang, Y.; Su, J.G.; Zhang, J.; Yang, T.; et al. Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients: A randomized controlled phase 2 trial. *medRxiv* 2022. [CrossRef]

46. Naito, T.; Tsuchida, N.; Kusunoki, S.; Kaneko, Y.; Tobita, M.; Ito, S. Reactogenicity and immunogenicity of BNT162b2 or mRNA-1273 COVID-19 booster vaccinations after two doses of BNT162b2 among healthcare workers in Japan: A prospective observational study. *Expert Rev. Vaccines* 2022, 1–11. [CrossRef]

47. Adams, K.; Rhoads, J.P.; Surie, D.; Gaglani, M.; Ginde, A.A.; McNeal, T.; Ghamande, S.; Huynh, D.; Talbot, H.K.; Casey, J.D.; et al. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States. *medRxiv* 2022. [CrossRef]

48. Bar-On, Y.M.; Goldberg, Y.; Mandel, M.; Bodenheimer, O.; Freedman, L.; Kalkstein, N.; Mizrahi, B.; Alroy-Preis, S.; Ash, N.; Milo, R.; et al. Protection of BNT162b2 Vaccine Booster against COVID-19 in Israel. *N. Engl. J. Med.* 2021, 385, 1393–1400. [CrossRef]

49. Burckhardt, R.M.; Dennehy, J.J.; Poon, L.L.M.; Saif, L.J.; Enquist, L.W. Are COVID-19 Vaccine Boosters Needed? The Science behind Boosters. *J. Virol.* 2022, 96, e0197321. [CrossRef]

50. Plumb, I.D.; Feldstein, L.R.; Barkley, E.; Posner, A.B.; Bregman, H.S.; Hagen, M.B.; Gerhart, J.L. Effectiveness of COVID-19 mRNA Vaccination in Preventing COVID-19-Associated Hospitalization among Adults with Previous SARS-CoV-2 Infection—United States, June 2021–February 2022. *MMWR Morb. Mortal. Wkly. Rep.* 2022, 71, 549–555. [CrossRef]

51. Korves, C.; Izurieta, H.S.; Smith, J.; Zwain, G.M.; Powell, E.I.; Balajee, A.; Ryder, K.M.; Young-Xu, Y. Relative effectiveness of booster vs. 2-dose mRNA COVID-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis. *Vaccine* 2022, 40, 4742–4747. [CrossRef]

52. Du, Y.; Chen, L.; Shi, Y. Booster COVID-19 vaccination against the SARS-CoV-2 Omicron variant: A systematic review. *Hum. Vaccines Immunother.* 2022, 18, 2062983. [CrossRef] [PubMed]